Top

Journal of Cachexia, Sarcopenia and Muscle

Published in:

01-12-2012 | Review

Research on cachexia, sarcopenia and skeletal muscle in cardiology

Author: Andrew J. S. Coats

Published in: Journal of Cachexia, Sarcopenia and Muscle | Issue 4/2012

Abstract

Background

The awareness of cardiac cachexia, i.e. involuntary weight loss in patients with underlying cardiovascular disease, has increased over the last two decades.

Methods and results

This mini-review looks at recent research in the cardiovascular literature that is relevant to the areas of interest of the Journal of Cachexia, Sarcopenia and Muscle. It identifies significant research in the last 3 years on the obesity paradox, the causes and effects of skeletal muscle wasting, animal models of cachexia and emerging treatment ideas in cardiac cachexia.

Conclusions

Assuming a similar literature in the fields of cancer, chronic obstructive pulmonary disease, chronic renal failure and chronic liver failure, the emergence of cachexia as a vibrant area of clinical and experimental research seems assured.

Marinou K, Tousoulis D, Antonopoulos AS, Stefanadi E, Stefanadis C. Obesity and cardiovascular disease: from pathophysiology to risk stratification. Int J Cardiol. 2010;138:3–8.PubMedCrossRef

Thompson AM, Zhang Y, Tong W, et al. Association of obesity and biomarkers of inflammation and endothelial dysfunction in adults in Inner Mongolia, China. Int J Cardiol. 2011;150:247–52.PubMedCrossRef

Younge JO, Damen NL, van Domburg RT, Pedersen SS. Obesity, health status, and 7-year mortality in percutaneous coronary intervention: in search of an explanation for the obesity paradox. Int J Cardiol. 2012. doi:10.1016/j.ijcard.2012.03.105.

Trullàs JC, Formiga F, Montero M, the RICA Investigators, et al. Impact of weight loss on mortality in chronic heart failure: findings from the RICA Registry. Int J Cardiol. 2012. doi:10.1016/j.ijcard.2012.09.062.

Zamora E, Lupón J, de Antonio M, et al. The obesity paradox in heart failure: is etiology a key factor? Int J Cardiol. 2011. doi:10.1016/j.ijcard.2011.11.022.

Tepsuwan T, Schuarattanapong S, Woragidpoonpol S, et al. Incidence and impact of cardiac cachexia in valvular surgery. Geol Geofiz. 2009;17:617–21.

Clark AL, Anker SD. Body mass, chronic heart failure, surgery and survival. J Heart Lung Transplant. 2010;29:261–4.PubMedCrossRef

Ege MR, Altay H. The impact of body mass index on clinical outcomes after acute myocardial infarction. Int J Cardiol. 2010;145:539.PubMedCrossRef

Aronson D, Nassar M, Goldberg T, Kapeliovich M, Hammerman H, Azzam ZS. The impact of body mass index on clinical outcomes after acute myocardial infarction. Int J Cardiol. 2010;145:476–80.PubMedCrossRef

10.

Long MJ, Jiang CQ, Lam TH, Xu L, Zhang WS, Lin JM, Ou JP, Cheng KK. Atrial fibrillation and obesity among older Chinese: the Guangzhou Biobank Cohort Study. Int J Cardiol. 2011;148:48–52.PubMedCrossRef

11.

Doehner W, Erdmann E, Cairns R, Clark AL, Dormandy JA, Ferrannini E, Anker SD. Inverse relation of body weight and weight change with mortality and morbidity in patients with type 2 diabetes and cardiovascular co-morbidity: an analysis of the PROactive study population. Int J Cardiol. 2011. doi:10.1016/j.ijcard.2011.09.03.

12.

Zavin A, Daniels K, Arena R, Allsup K, Lazzari A, Joseph J, Schulze PC, Lecker SH, Forman DE. Adiposity facilitates increased strength capacity in heart failure patients with reduced ejection fraction. Int J Cardiol. 2012. doi:10.1016/j.ijcard.2012.06.00.

13.

de Simone G, Pasanisi F, Ferrara AL, Roman MJ, Lee ET, Contaldo F, Howard BV, Devereux RB. Relative fat-free mass deficiency and left ventricular adaptation to obesity: The Strong Heart Study. Int J Cardiol. 2012. doi:10.1016/j.ijcard.2012.09.055.

14.

Piepoli MF, Guazzi M, Boriani G, et al. Exercise intolerance in chronic heart failure: mechanisms and therapies. Part II. Eur J Cardiovasc Prev Rehabil. 2010;17:643–8.PubMedCrossRef

15.

Toth MJ, Shaw AO, Miller MS, VanBuren P, LeWinter MM, Maughan DW, et al. Reduced knee extensor function in heart failure is not explained by inactivity. Int J Cardiol. 2010;143:276–82. Epub 2009 Mar 27.PubMedCrossRef

16.

Georgiadou P, Adamopoulos S. Skeletal muscle abnormalities in chronic heart failure. Curr Heart Fail Rep. 2012;9:128–32 .PubMedCrossRef

17.

Bing C. Lipid mobilization in cachexia: mechanisms and mediators. Curr Opin Support Pall Care. 2011;5:356–60.

18.

Fearon KC. Cancer cachexia and fat-muscle physiology. N Engl J Med. 2011;365:565–7.PubMedCrossRef

19.

Filusch A, Ewert R, Altesellmeier M, Zugck C, Hetzer R, Borst MM, Katus HA, Meyer FJ. Respiratory muscle dysfunction in congestive heart failure—the role of pulmonary hypertension. Int J Cardiol. 2011;150:182–5.PubMedCrossRef

20.

Lourenço AP, Fontoura D, Henriques-Coelho T, Leite-Moreira AF. Current pathophysiological concepts and management of pulmonary hypertension. Int J Cardiol. 2012;155:350–61.PubMedCrossRef

21.

Tian M, Asp ML, Nishijima Y, Belury MA. Evidence for cardiac atrophic remodeling in cancer-induced cachexia in mice. Int J Oncol. 2011;39:1321–6.PubMed

22.

Tian M, Nishijima Y, Asp ML, Stout MB, Reiser PJ, Belury MA. Cardiac alterations in cancer-induced cachexia in mice. Int J Oncol. 2010;37:347–53.PubMed

23.

Zastrow A, Wolf J, Giannitsis E, Katus H, Herzog W, Friederich HC, Mussler C. Elevated myocardial enzymes and natriuretic peptides in anorexia nervosa: prototypic condition for the pathophysiology of cachexia? Cardiology. 2011;118:256–9.PubMedCrossRef

24.

Araújo JP, Lourenço P, Rocha-Gonçalves F, Ferreira A, Bettencourt P. Nutritional markers and prognosis in cardiac cachexia. Int J Cardiol. 2011;146:359–63.PubMedCrossRef

25.

Amarelli C, Buonocore M, Romano G, Maiello C, De Santo LS. Nutritional issues in heart transplant candidates and recipients. Front Biosci. 2012;4:662–8.

26.

Anker SD, Laviano A, Filippatos G, et al. ESPEN Guidelines on Parenteral Nutrition: on cardiology and pneumology. Clin Nutr. 2009;28:455–60.PubMedCrossRef

27.

Celık T, Yuksel UC. The small intestine in cardiac cachexia: a forgotten player of the game. Int J Cardiol. 201;147:186–7.CrossRef

28.

Sandek A, Valentova M, von Haehling S, Doehner W, Anker SD. The small intestine: a critical linkage in pathophysiology of cardiac cachexia. Int J Cardiol. 2011;146:277–8.PubMedCrossRef

29.

Celik T, Iyisoy A, Yuksel UC, Jata B. The small intestine: a critical linkage in pathophysiology of cardiac cachexia. Int J Cardiol. 2010;143:200–1.PubMedCrossRef

30.

Attanasio P, Anker SD, Doehner W, von Haehling S. Hormonal consequences and prognosis of chronic heart failure. Curr Opin Endocrinol Diabet Obes. 2011;18:224–30.CrossRef

31.

Vaz Pérez A, Doehner W, von Haehling S, Schmidt H, Zimmermann AV, Volk HD, Anker SD, Rauchhaus M. he relationship between tumor necrosis factor-α, brain natriuretic peptide and atrial natriuretic peptide in patients with chronic heart failure. Int J Cardiol. 2010;141:39–43.PubMedCrossRef

32.

Chauhan A, Sequeria A, Manderson C, Maddocks M, Wasley D, Wilcock A. Exploring autonomic nervous system dysfunction in patients with cancer cachexia: a pilot study. Auton Neurosci-Bas Clin. 2012;166:93–5.CrossRef

33.

Hagenah GC, Luers C, Prager D, Blaschke S. Association of Cheyne-Stokes respiration and cardiac cachexia in congestive heart failure. Int J Cardiol. 2010;142:298–300.PubMedCrossRef

34.

Yoshida T, Semprun-Prieto L, Wainford RD, Sukhanov S, Kapusta DR, Delafontaine P. Angiotensin II, reduces food intake by altering orexigenic neuropeptide expression in the mouse hypothalamus. Endocrinology. 2012;153:1411–20.PubMedCrossRef

35.

Breit SN, Johnen H, Cook AD, Tsai VW, Mohammad MG, Kuffner T, Zhang HP, Marquis CP, Jiang L, Lockwood G, Lee-Ng M, Husaini Y, Wu L, Hamilton JA, Brown DA. The TGF-beta superfamily cytokine, MIC-1/GDF15: a pleotrophic cytokine with roles in inflammation, cancer and metabolism. Growth Factors. 2011;29:187–95.PubMedCrossRef

36.

Singh M, Bedi US, Singh PP, Arora R, Khosla S. Leptin and the clinical cardiovascular risk. Int J Cardiol. 2010;140:266–71.PubMedCrossRef

37.

Araujo JP, Lourenco P, Rocha-Goncalves F, Ferreira A, Bettencourt P. Adiponectin is increased in cardiac cachexia irrespective of body mass index. Eur J Hear Fail. 2009;11:567–72.CrossRef

38.

Tedeschi S, Pilotti E, Parenti E, et al. Serum adipokine zinc alpha2-glycoprotein and lipolysis in cachectic and noncachectic heart failure patients: relationship with neurohormonal and inflammatory biomarkers. Metab Clin Exp. 2012;61:37–42.PubMedCrossRef

39.

Celik T, Yaman H. Elevated adiponectin levels in patients with chronic heart failure: an independent predictor of mortality or a marker of cardiac cachexia? Int J Cardiol. 2010;144:319–20.PubMedCrossRef

40.

Szabo T, von Haehling S, Habedank D, Rauchhaus M, Lainscak M, Sandek A, Schefold J, Anker SD, Doehner W. Usefulness of minimal modelling to assess impaired insulin sensitivity in patients with chronic heart failure. Int J Cardiol. 2011;147:47–51.PubMedCrossRef

41.

Dalla Libera L, Ravara B, Gobbo V, Betto DD, Germinario E, Angelini A, Evangelista S, Vescovo G. Skeletal muscle proteins oxidation in chronic right heart failure in rats: can different beta-blockers prevent it to the same degree? Int J Cardiol. 2010;143:192–9.PubMedCrossRef

42.

Maccio A, Madeddu C, Gramignano G, et al. A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: evaluating the impact on metabolic and inflammatory profiles and quality of life. Gynecol Oncol. 2012;124:417–25.PubMedCrossRef

43.

Penet MF, Winnard Jr PT, Jacobs MA, Bhujwalla ZM. Understanding cancer-induced cachexia: imaging the flame and its fuel. Curr Opin Support Pall Care. 2011;5:327–33.

44.

Oreopoulos A, Kalantar-Zadeh K, McAlister FA, et al. Comparison of direct body composition assessment methods in patients with chronic heart failure. J Card Fail. 2010;16:867–72.PubMedCrossRef

45.

Halliday V, Porock D, Arthur A, Manderson C, Wilcock A. Development and testing of a cancer appetite and symptom questionnaire. J Hum Nutr Diet. 2012;25:217–24.PubMedCrossRef

46.

Blum D, Strasser F. Cachexia assessment tools. Curr Opin Support Pall Care. 2011;5:350–5.

47.

von Haehling S, Stepney R. Anker SD Advances in understanding and treating cardiac cachexia: highlights from the 5th Cachexia Conference. Int J Cardiol. 2010;144:347–9.CrossRef

48.

Watkins F, Tulloch S, Bennett C, Webster B, McCarthy C. A multimodal, interdisciplinary programme for the management of cachexia and fatigue. Int J Palliat Nurs. 2012;18:85–90.PubMed

49.

Maddocks M, Murton AJ, Wilcock A. Improving muscle mass and function in cachexia: non-drug approaches. Curr Opin Support Pall Care. 2011;5:361–4.

50.

Lourenco AP, Vasques-Novoa F, Fontoura D, Bras-Silva C, Roncon-Albuquerque Jr R, Leite-Moreira AF. A Western-type diet attenuates pulmonary hypertension with heart failure and cardiac cachexia in rats. J Nutr. 2011;141:1954–60.PubMedCrossRef

51.

Timmerman KL, Rasmussen BB. Does a reduction in anabolic signaling contribute to muscle wasting in chronic heart failure? J Appl Physiol. 2011;110:869–70.PubMedCrossRef

52.

Akamizu T, Kangawa K. Therapeutic applications of ghrelin to cachexia utilizing its appetite-stimulating effect. Peptides. 2011;32:2295–300.PubMedCrossRef

53.

Lund LH, Williams JJ, Freda P, et al. Ghrelin resistance occurs in severe heart failure and resolves after heart transplantation. Eur J Hear Fail. 2009;11:789–94.CrossRef

54.

DeBoer MD. Ghrelin and cachexia: will treatment with GHSR-1a agonists make a difference for patients suffering from chronic wasting syndromes? Mol Cell Endocrinol. 2011;340:97–105.PubMedCrossRef

55.

Xin X, Ren AJ, Zheng X, et al. Disturbance of circulating ghrelin and obestatin in chronic heart failure patients especially in those with cachexia. Peptides. 2009;30:2281–5.PubMedCrossRef

56.

Miki K, Maekura R, Nagaya N, et al. Ghrelin treatment of cachectic patients with chronic obstructive pulmonary disease: a multicenter, randomized, double-blind, placebo-controlled trial. PLoS One. 2012;7:e35708.PubMedCrossRef

57.

Angelidis G, Valotassiou V, Georgoulias P. Current and potential roles of ghrelin in clinical practice. J Endocrinol Investig. 2010;33:823–38.

58.

Ledderose C, Kreth S, Beiras-Fernandez A. Ghrelin, a novel peptide hormone in the regulation of energy balance and cardiovascular function. Recent Pat Endocr Metab Immune Drug Discov. 2011;5:1–6.PubMedCrossRef

59.

Breitbart A, Auger-Messier M, Molkentin JD, Heineke J. Myostatin from the heart: local and systemic actions in cardiac failure and muscle wasting. Am J Physiol Heart Circ Physiol. 2011;300:H1973–82.PubMedCrossRef

60.

Springer J, Adams V, Anker SD. Myostatin: regulator of muscle wasting in heart failure and treatment target for cardiac cachexia. Circulation. 2010;121:354–6.PubMedCrossRef

61.

Heineke J, Auger-Messier M, Xu J, Sargent M, York A, Welle S, Molkentin JD. Genetic deletion of myostatin from the heart prevents skeletal muscle atrophy in heart failure. Circulation. 2010;121:419–25.PubMedCrossRef

62.

Murphy KT, Chee A, Gleeson BG, Naim T, Swiderski K, Koopman R, et al. Antibody-directed myostatin inhibition enhances muscle mass and function in tumor-bearing mice. Am J Physiol Regul Integr Comp Physiol. 2011;301:R716–26.PubMedCrossRef

63.

Scarlett JM, Bowe DD, Zhu X, Batra AK, Grant WF, Marks DL. Genetic and pharmacologic blockade of central melanocortin signaling attenuates cardiac cachexia in rodent models of heart failure. J Endocrinol. 2010;206:121–30.PubMedCrossRef

64.

MacDonald N. Chronic inflammatory states: their relationship to cancer prognosis and symptoms. J Roy Coll Physic Edinburgh. 2011;41:246–53.CrossRef

65.

Argiles JM, Busquets S, Lopez-Soriano FJ. Anti-inflammatory therapies in cancer cachexia. Eur J Pharmacol. 2011;668:S81–6.PubMedCrossRef

66.

Shadfar S, Couch ME, McKinney KA, et al. Oral resveratrol therapy inhibits cancer-induced skeletal muscle and cardiac atrophy in vivo. Nutr Canc. 2011;63:749–62.CrossRef

Title: Research on cachexia, sarcopenia and skeletal muscle in cardiology
Author: Andrew J. S. Coats
Publication date: 01-12-2012
Publisher: Springer-Verlag
Published in: Journal of Cachexia, Sarcopenia and Muscle / Issue 4/2012
Print ISSN: 2190-5991
Electronic ISSN: 2190-6009
DOI: https://doi.org/10.1007/s13539-012-0090-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods and results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2012

Cancer cachexia and anabolic interventions: a case report

Consilience in sarcopenia of cirrhosis

Anorexia/cachexia of chronic diseases: a role for the TGF-β family cytokine MIC-1/GDF15

Cancer cachexia is associated with a decrease in skeletal muscle mitochondrial oxidative capacities without alteration of ATP production efficiency

From muscle wasting to sarcopenia and myopenia: update 2012

Ursodeoxycholic acid and its emerging role in attenuation of tumor growth in gastrointestinal malignancies

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials